Atherosclerotic Renal Artery Stenosis: What You Need to Know About Diagnosis, Treatment, and Next Steps
If you’re over 65, have diabetes, or struggle with hard-to-control high blood pressure, you might be at risk for a silent but serious condition: atherosclerotic renal artery stenosis (ARAS). This common kidney blood vessel disease develops when plaque builds up in the arteries that supply blood to your kidneys, narrowing them over time. While many people with ARAS have no symptoms, the disease can lead to resistant hypertension (high blood pressure that won’t respond to medications), kidney damage, or even life-threatening heart complications like flash pulmonary edema (sudden fluid buildup in the lungs). Worse yet, having ARAS increases your risk of cardiovascular death—a critical reason to understand how to manage it.
Ying Jiang and Ming-Hua Zhang, cardiologists at the Second Medical Center of the Chinese People’s Liberation Army General Hospital in Beijing, recently shared their insights on ARAS in a Chinese Medical Journal viewpoint. Their work highlights a shifting landscape in how doctors approach this condition—especially when it comes to whether to use medications alone or add procedures like stenting. Let’s break down what you need to know.
How Common Is ARAS?
ARAS isn’t rare—it’s most prevalent in older adults, people with diabetes, and those with other forms of atherosclerosis (like coronary artery disease). For example, 11.3% to 39% of people with ARAS also have coronary artery disease, according to a study in Journal of Interventional Cardiology. The true number of cases is likely even higher because most people with mild ARAS have no symptoms.
Why Early Diagnosis Is Tricky (and Why It Matters)
The biggest challenge with ARAS is that it’s often asymptomatic—meaning it doesn’t cause noticeable signs until it’s severe. The gold standard for diagnosis is renal artery angiography, a test that uses contrast dye and X-rays to see inside the arteries. But angiography is expensive and carries risks (like contrast-induced kidney damage), so doctors need simpler tools to spot ARAS early.
That’s where risk scores come in. Jiang and Zhang’s team developed a simple scoring model to predict ARAS risk, while another study in Nephron created a similar tool for both clinical and research use. These scores look at red flags like:
- Epigastric (upper belly) bruits (abnormal sounds)
- Uncontrolled hypertension
- Diabetes or high cholesterol
- A history of other atherosclerotic diseases
Importantly, smoking wasn’t a strong predictor of ARAS in their analysis—a key reminder that risk factors vary.
When to Suspect Severe ARAS
While mild ARAS may fly under the radar, severe cases (narrowing >70%) can cause obvious problems. Watch for these warning signs:
- Recurrent flash pulmonary edema: Sudden shortness of breath from fluid in the lungs—this is a major red flag for severe ARAS.
- Refractory hypertension: High blood pressure that won’t improve with three or more medications.
- Worsening kidney function: A drop in your estimated glomerular filtration rate (eGFR), a measure of kidney health.
If you have any of these, your doctor should check for ARAS immediately.
The Big Shift in Treatment: Medications First
For years, doctors often recommended renal artery stenting (a procedure to open narrowed arteries with a small metal tube) for ARAS. But three large randomized controlled trials (the gold standard of medical research) changed the guidelines: they found no benefit from stenting for most patients compared to optimal medical therapy (OMT)—the combination of blood pressure medications, cholesterol-lowering drugs (like statins), and antiplatelet agents (like aspirin).
Today, OMT is the first-line treatment for ARAS. It works well for mild narrowing (<50%) and even some moderate cases (50-70%)—as long as your blood pressure and kidney function are stable.
When Stenting Makes Sense
But stenting isn’t obsolete. It does help carefully selected patients—especially those with:
- Resistant hypertension: Blood pressure that won’t budge despite OMT.
- Ischemic nephropathy: Kidney damage from reduced blood flow.
- Cardiac destabilization: Conditions like recurrent heart failure or flash pulmonary edema.
Studies back this up. For example:
- A Kidney Research and Clinical Practice study found that 65% of high-risk ARAS patients had better blood pressure control after stenting, and 30-40% saw improved kidney function.
- A American Journal of Hypertension trial showed that stenting reduced left ventricular (heart muscle) mass in hypertensive ARAS patients—lowering their risk of heart problems over time.
Even in extreme cases (like a completely blocked renal artery with an atrophied kidney), stenting can help refractory hypertension, according to a 2021 Internal Medicine case report.
The Gray Area: Moderate Narrowing (50-70%)
What about cases where the artery is narrowed 50-70%? This is the trickiest group. Doctors need to check if the narrowing is hemodynamically significant—meaning it’s actually reducing blood flow to the kidney. They use tests like:
- Pressure gradients: A resting or exercise-induced systolic pressure difference >20 mmHg across the narrowed spot.
- Renal fractional flow reserve (FFR): A measure of blood flow—an FFR ≤0.8 means the narrowing is harmful.
If these tests confirm the narrowing is causing problems, stenting may be worth it.
What the Latest Research Says About Revascularization
A 2021 meta-analysis (a study that combines data from multiple trials) in Journal of International Medical Research summed it up: stenting plus OMT reduces refractory hypertension—but it doesn’t lower the risk of stroke, kidney failure, or death unless patients are carefully chosen. The key takeaway? Stenting isn’t a “one-size-fits-all” solution—it’s only helpful for people with severe, symptomatic ARAS.
The Future of ARAS Care
Doctors and researchers are working to solve two big problems:
- Better patient selection: Creating simpler risk scores and non-invasive imaging tools (like MRI or CT angiography) to find ARAS early and pick who will benefit from stenting.
- Novel therapies: Exploring new drugs, gene therapy, or cell-based treatments to slow plaque buildup or repair kidney damage.
The Bottom Line
For most people with ARAS, OMT is the best first step. But if you have refractory hypertension, kidney damage from reduced blood flow, or recurrent heart failure, stenting could be life-changing. The key is working with your doctor to:
- Monitor your risk factors (blood pressure, cholesterol, diabetes).
- Use simple tools (like risk scores) to spot ARAS early.
- Get tested for hemodynamic significance if you have moderate narrowing.
ARAS is a silent threat—but with the right approach, we can manage it effectively.
References
- Murphy TP, et al. Hypertension. 2016;68:1145–1152. doi:10.1161/HYPERTENSIONAHA.116.07744
- Siddiqui EU, et al. J Vasc Interv Radiol. 2018;29:966–970. doi:10.1016/j.jvir.2018.03.003
- Zachrisson K, et al. Blood Press. 2020;29:285–290. doi:10.1080/08037051.2020.1756740
- Zeller T. J Interv Cardiol. 2005;18:497–506. doi:10.1111/j.1540-8183.2005.00092.x
- Schreiber MJ, et al. Urol Clin North Am. 1984;11:383–392.
- de Leeuw PW, et al. Curr Hypertens Rep. 2018;20:35. doi:10.1007/s11906-018-0829-3
- Peng M, et al. J Hum Hypertens. 2016;30:124–128. doi:10.1038/jhh.2015.40
- Khatami MR, et al. Nephron. 2018;140:257–264. doi:10.1159/000492732
- Kim S, et al. Kidney Res Clin Pract. 2019;38:336–346. doi:10.23876/j.krcp.18.0148
- Iwashima Y, et al. Am J Hypertens. 2020;33:570–580. doi:10.1093/ajh/hpaa036
- Sasaki Y, et al. Intern Med. 2021;60:287–292. doi:10.2169/internalmedicine.5290-20
- Chen Y, et al. J Int Med Res. 2021;49:300060520983585. doi:10.1177/0300060520983585
Original study by Ying Jiang and Ming-Hua Zhang, Chinese Medical Journal. 2021;134(12):1402–1404. doi:10.1097/CM9.0000000000001576
Was this helpful?
0 / 0